About APCI

APCI logo

Not a member?
Join today!

(800) 532-2724

Since 1984, APCI has been the ‘united voice of independent pharmacy’

APCI began as a small buying group for a limited number of independent pharmacies in central Alabama. Since that time, the cooperative has grown to more than 1,800 members pharmacies in 26 states, and provides its members with a wide range of products and services.

Our mission is to represent the economic and professional interests of independent pharmacies by providing leadership, vision, and a collective voice for our members in the healthcare marketplace. Our goal is to level the playing field for our member pharmacies by providing innovative, targeted programs to benefit our entire membership.

21

Nov

2014

U.S. Senate committee holds hearing on generic pricing [LINKS]

Recent price spikes for what were up until recently low-cost generic drugs prompted a Senate committee to look into the issue.


20

Nov

2014

Cigna Migration: RxBIN/RxPCN Information

Effective 1/1/15, Cigna is migrating it’s Med D (including Healthspring) business from Argus to RxClaim .  As a result of this migration members will be provided with new pharmacy insurance cards with new BIN/PCN information that will need to be updated in the members profile. 

20

Nov

2014

Aetna Medicare Rx Premier (PDP) and First Health Part D Premier Plus (PDP)

Effective 1/1/2015, APNS member pharmacies will be participating in two NEW open networks with Aetna/ BIN number 610502.   These are NOT preferred networks.   

  • - Aetna Medicare Rx Premier(PDP)
  • - First Health Part D Premier Plus (PDP)

18

Nov

2014

Future Scripts®: IMPORTANT PROVIDER NOTICE Medicare Part D Information

FutureScripts® a Catamaran Company™

BIN:  610011   PCN:  CTRXMEDD   RxGrp:  MDCMEDD

Independence Blue Cross (IBC) a client of FutureScripts® a Catamaran Company™, is making some changes Effective 1/1/2015.

18

Nov

2014

Prime Therapeutics: Insulin Products with Preferred Status

Commercial and Exhange Market formularies

Effective January 1, 2015, Novolin, Novolog, Lantus and Levemir will be the insulin products with preferred status for Commercial and Exchange Market formularies.

First963965Last